PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction

BACKGROUND: Cancer therapies inhibiting PI3Kα (phosphoinositide 3‐kinase‐α)–dependent growth factor signaling, including trastuzumab inhibition of HER2 (Human Epidermal Growth Factor Receptor 2), can cause adverse effects on the heart. Direct inhibition of PI3Kα is now in clinical trials, but the ef...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Am Heart Assoc
Autors principals: McLean, Brent A., Patel, Vaibhav B., Zhabyeyev, Pavel, Chen, Xueyi, Basu, Ratnadeep, Wang, Faqi, Shah, Saumya, Vanhaesebroeck, Bart, Oudit, Gavin Y.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512135/
https://ncbi.nlm.nih.gov/pubmed/31039672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.010961
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars